1 Year Experience With The Unique Two Component Gore Tigris Stent In The SFA And Popliteal Artery: What Are Its Unique Advantages And Limitations

Andrej Schmidt, MD
Division of Interventional Angiology
University Hospital Leipzig, Germany

Potential conflicts of interest

Speaker’s name: Andrej Schmidt

✓ I have the following potential conflicts of interest to report:
Consulting:
Medtronic, Abbott, Boston Scientific, Cook, Cordis, C.R. Bard, Intactvascular, ReFlow Medical, Spectranetics, Upstream Peripheral

Design of the Gore Tigris Vascular Stent

- Collaterales are not jeopardized
- No metallic bridges → highly flexible

Tigris® – the Leipzig Experience

- 40 lesions in SFA and Popliteal Artery
- 75% claudicants
- Mean lesion length 43.1 ± 27.8 mm
- 2 CTOs

<table>
<thead>
<tr>
<th>Prox. SFA</th>
<th>Med. SFA</th>
<th>Dist. SFA</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.0 %</td>
<td>36.2 %</td>
<td>12.8 %</td>
<td>10.6 %</td>
<td>17.0 %</td>
<td>6.4 %</td>
</tr>
</tbody>
</table>

Calcification

<table>
<thead>
<tr>
<th>none/mild</th>
<th>moderate</th>
<th>severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 %</td>
<td>40 %</td>
<td>15 %</td>
</tr>
</tbody>
</table>

Leipzig Single Center Registry Tigris Stent: Results

12 month follow-up
- Restenosis rate 12.5 %
- Primary patency 85.5 %
- Freedom from TLR 90.0 %

Tigris® in the Popliteal Artery

- 50 lesions in distal SFA und Popliteal Artery
- Critical limb ischemia in 70 %
- Mean lesion length 114.2 ± 36.9 mm
- 37 CTOs (74%)

<table>
<thead>
<tr>
<th>Distal SFA - P1</th>
<th>Distal SFA - P2</th>
<th>Distal SFA - P3</th>
<th>P1 – P2</th>
<th>P1 – P3</th>
<th>P2 – P3</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.0 %</td>
<td>18.0 %</td>
<td>10.0 %</td>
<td>16.0 %</td>
<td>26.0 %</td>
<td>8.0 %</td>
</tr>
</tbody>
</table>

Calcification

<table>
<thead>
<tr>
<th>none/mild</th>
<th>moderate</th>
<th>severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>54 %</td>
<td>26 %</td>
<td>20 %</td>
</tr>
</tbody>
</table>
Tigris® in the Popliteal Artery: Restenosis-Rate

Parthipun et al, Cardiovasc Intervent Radiol 2015

at 6 months: 10.4 %
at 12 months: 51.4 %

(PSVR > 2.0)

Tigris® in the Popliteal Artery: Primary Patency

Parthipun et al, Cardiovasc Intervent Radiol 2015

at 6 months: 95.0 %
at 12 months: 69.5 %

Interrupted vessel patency and no clinically driven reintervention

Tigris® in the Popliteal Artery: Freedom from TLR

Parthipun et al, Cardiovasc Intervent Radiol 2015

at 6 months: 95.7 %
at 12 months: 86.1 %

Limb-salvage at 1 year: 95.8 %

Tigris® in the Popliteal Artery
Comparison of Different Stents and Trials

Parthipun et al, Cardiovasc Intervent Radiol 2015

Different restenosis-criteria (PSVR)

Advantages of the Tigris-Stent?

Parthipun et al, Cardiovasc Intervent Radiol 2015

Tigris-stent shows high flexibility in popliteal arteries

Tigris-Stent does not jeopardize collaterals
Tigris-Stent to Preserve Collaterales

Viabahn 6.0/250mm +
Trigris 6.0/60mm distal

Tigris® Vascular Stents

First results in shorter fem-pop lesions as well as in more complex popliteal lesions are promising.

Comparing trials have to define the place of the Trigis-stent in todays landscape of treatment-options for the femoro-popliteal tract.